Body Fat Distribution, Sleep Disorder
Conditions
Keywords
obstructive sleep apnea, normal weight obesity
Brief summary
Comparison of the prevalence of obstructive sleep apnea (OSA), measured by polysomnography in normal weight patients with central obesity by body mass index (BMI) and waist hip ratio (WHR), with normal weight patients without central obesity by BMI and WHR. Evaluation of arterial stiffness and vascular age in normal weight patients with central obesity and in normal weight patients without central obesity. Determination of the exercise response characteristics in OSA patients.
Detailed description
Body composition (the distribution of adipose tissue) appears to be a risk factor for the prevalence of obstructive form of sleep apnea. The investigators expect a higher prevalence of this serious sleep pathology in normal weight patients with central obesity than in normal weight patient without central obesity. In normal weight patients with central obesity also endothelial dysfunctions, abnormal exercise response to dynamic load and abnormal circadian patterns of blood pressure and heart rate can be expected. There are theoretical assumptions for this hypothesis but relevant studies on sufficiently large samples of patients have not been done. The investigators will also compare the lipid profile in normal weight patients with central obesity with those of normal weight patients without central obesity.
Interventions
Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
Sponsors
St. Anne's University Hospital Brno, Czech Republic
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
central obesity group: * BMI 18.5 - 24.9 kg/m2 for both men and women * WHR more than 0.9 for men and 0.85 for women * no history of myocardial infarction, stroke, atrial fibrillation, previous diagnosis of OSA or its treatment. Inclusion Criteria without central obesity group: * BMI 18.5 - 24.9 kg/m2 for men and women * WHR selected from the lowest tertile of WHR distribution for both men and women
Exclusion criteria
* acute infection * known diagnosis of chronic renal or cardiac failure * taking drugs that affect sleep (stimulants, hypnotics, antidepressants, antipsychotics, anxiolytics, antihistamines, corticosteroids, theophylline, anti-parkinsonic drugs, anticonvulsants, morphine-type analgetics)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Apnea hypopnea index | Through study completion, an average of 1 year | Apnea hypopnea index will be measured in both groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardio Ankle Vascular Index (CAVI) | Through study completion, an average of 1 year | Noninvasive arterial stiffness and vascular age index CAVI will be measured in both groups |
| Response on ergo-spirometry test | Through study completion, an average of 1 year | Cardiopulmonary exercise test parameters (oxygen consumption at peak exercise (ml/kg/min) and VE/VCO2 slope) will be measured in both groups. |
| Ambulatory 24-hour blood pressure measurement (ABPM) | Through study completion, an average of 1 year | Ambulatory 24-hour blood pressure measurement (ABPM) will be analyzed conventionally and chronobiologically in both broups |
Countries
Czechia
Outcome results
None listed